Saturday, August 19, 2017 11:34:25 AM
So to recap.
Stellar quarter over quarter financials. Increasing revenues, decreasing debts.
FDA RMAT guidelines in 13 days which should shortly place RMAT on track again.
FDA hearings -stem cell testimonials (all positive)
Right to try law making its way to Trump's desk.
Texas already passed. GACP building clinic in Dallas and Florida.
Kuwait clinic being built.
Comella putting out publications every 10 seconds. Stellar speech at RAADFEST.
Almost no increase in outstanding shares.
No contravertible debt.
Kristen Comella as CEO.
General feeling toward stem cells amongst US citizens growing more positive and aware each day.
Thousands of happy customers.
All for under .03. When just mathematically on current revenues alone this should be .12-13c.
Wow.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM